Weidong Wei
Impact in
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Geriatrics and Gerontology top 5%
- Sirtuins and Resveratrol in Medicine
Papers in
- Oncology 12
- HER2/EGFR in Cancer Research 3
- PARP inhibition in cancer therapy 3
- Cancer Cells and Metastasis 2
-
- MicroRNA in disease regulation 5
- Cancer-related molecular mechanisms research 3
- Cancer, Lipids, and Metabolism 3
- Co-authors
- Xiaoming Xie (19 shared papers)Hailin Tang (16 shared papers)Danian Dai (9 shared papers)Yanan Kong (13 shared papers)Xinhua Xie (10 shared papers)Lu Yang (9 shared papers)Bo Chen (2 shared papers)Xiaojia Huang (3 shared papers)
- Journals
- Journal of Cancer (4 papers)PLoS ONE (3 papers)Cancer Letters (2 papers)Medical Oncology (2 papers)Frontiers in Oncology (2 papers)
- Partner nations
- ChinaUnited StatesSwitzerland
In The Last Decade
Weidong Wei
38 papers receiving 1.5k citations
Peers
Comparison fields: 5 of 120
- Cancer Research 551
- Geriatrics and Gerontology 63
- Oncology 278
- Surfaces, Coatings and Films 73
- Molecular Biology 677
Countries citing papers authored by Weidong Wei
This map shows the geographic impact of Weidong Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weidong Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weidong Wei more than expected).
Fields of papers citing papers by Weidong Wei
This network shows the impact of papers produced by Weidong Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weidong Wei. The network helps show where Weidong Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Weidong Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 217 | |
| 2 | 2020 | 136 | |
| 3 | 2015 | 123 | |
| 4 | 2013 | 94 | |
| 5 | 2012 | 89 | |
| 6 | 2014 | 84 | |
| 7 | 2018 | 73 | |
| 8 | 2012 | 73 | |
| 9 | 2019 | 73 | |
| 10 | 2018 | 59 | |
| 11 | 2016 | 54 | |
| 12 | 2018 | 50 | |
| 13 | 2016 | 39 | |
| 14 | 2018 | 36 | |
| 15 | 2015 | 35 | |
| 16 | 2011 | 30 | |
| 17 | 2016 | 28 | |
| 18 | 2022 | 28 | |
| 19 | 2016 | 26 | |
| 20 | 2008 | 23 |
About Weidong Wei
Weidong Wei is a scholar working on Oncology, Cancer Research, Molecular Biology, Surgery and Pulmonary and Respiratory Medicine, having authored 38 papers that have together received 1.5k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (5 papers), HER2/EGFR in Cancer Research (3 papers), Cancer-related molecular mechanisms research (3 papers), Cancer, Lipids, and Metabolism (3 papers), PARP inhibition in cancer therapy (3 papers), RNA Interference and Gene Delivery (2 papers), Advanced Sensor and Energy Harvesting Materials (2 papers) and Cancer Cells and Metastasis (2 papers). The work is most often cited by research in Cancer Research (551 citations), Geriatrics and Gerontology (63 citations), Oncology (278 citations), Surfaces, Coatings and Films (73 citations) and Molecular Biology (677 citations). Weidong Wei has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Xiaoming Xie, Hailin Tang, Danian Dai, Yanan Kong, Xinhua Xie, Lu Yang, Bo Chen, Xiaojia Huang, Bo Chen and Xiaoti Lin. Their work appears in journals such as Journal of Cancer, PLoS ONE, Cancer Letters, Medical Oncology and Frontiers in Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.